Welcome to our dedicated page for Celgene SEC filings (Ticker: CELG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Celgene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Celgene's regulatory disclosures and financial reporting.
Bristol Myers Squibb director Julia A. Haller exercised stock options to acquire 20,460 shares of common stock at $53.76 per share. The transaction on June 15, 2026 was a cash exercise, and she is holding all of the underlying shares.
Following this exercise, Haller directly owns 34,079 shares of Bristol Myers Squibb common stock, and the option covering these 20,460 shares has been fully exercised with no remaining balance.
Bristol Myers Squibb director Julia A. Haller exercised stock options to acquire 20,460 shares of common stock at $53.76 per share. The transaction on June 15, 2026 was a cash exercise, and she is holding all of the underlying shares.
Following this exercise, Haller directly owns 34,079 shares of Bristol Myers Squibb common stock, and the option covering these 20,460 shares has been fully exercised with no remaining balance.
Bristol Myers Squibb executive Wendy Short Bartie, EVP of Corporate Affairs, reported routine equity compensation transactions involving restricted stock units. She exercised 8,040 restricted stock units, each converting into one share of common stock, and a portion of the resulting shares was used to cover taxes.
The filing shows a tax-withholding disposition of 3,876 common shares at $54.72 per share to satisfy tax obligations upon vesting, not an open-market sale. After these transactions, she directly holds 12,081 shares of common stock. The restricted stock units vest annually in three equal installments beginning on June 3, 2025, and were scheduled compensation rather than discretionary trading.
Bristol Myers Squibb executive Wendy Short Bartie, EVP of Corporate Affairs, reported routine equity compensation transactions involving restricted stock units. She exercised 8,040 restricted stock units, each converting into one share of common stock, and a portion of the resulting shares was used to cover taxes.
The filing shows a tax-withholding disposition of 3,876 common shares at $54.72 per share to satisfy tax obligations upon vesting, not an open-market sale. After these transactions, she directly holds 12,081 shares of common stock. The restricted stock units vest annually in three equal installments beginning on June 3, 2025, and were scheduled compensation rather than discretionary trading.
Bristol-Myers Squibb Company reported voting results from its annual shareholder meeting. Shareholders elected all 11 director nominees to serve until the 2027 annual meeting, with each receiving over 1.46 billion votes in favor and substantial broker non-votes recorded.
Shareholders approved, on an advisory basis, the compensation of named executive officers with 1,459,162,310 votes for and 72,490,026 against, and also approved the Company’s 2026 stock award and incentive plan with 1,470,672,957 votes for and 63,896,918 against. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026 was ratified. A shareholder proposal to require the board chairperson to be an independent director did not pass, receiving 422,069,323 votes for and 1,109,378,680 votes against.
Bristol-Myers Squibb Company reported voting results from its annual shareholder meeting. Shareholders elected all 11 director nominees to serve until the 2027 annual meeting, with each receiving over 1.46 billion votes in favor and substantial broker non-votes recorded.
Shareholders approved, on an advisory basis, the compensation of named executive officers with 1,459,162,310 votes for and 72,490,026 against, and also approved the Company’s 2026 stock award and incentive plan with 1,470,672,957 votes for and 63,896,918 against. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026 was ratified. A shareholder proposal to require the board chairperson to be an independent director did not pass, receiving 422,069,323 votes for and 1,109,378,680 votes against.
Bristol Myers Squibb EVP and Chief Commercial Officer Adam Lenkowsky reported routine equity award activity involving market share units and common stock. On May 1, 2026, he exercised 1,373 market share units into common stock and recorded related adjustments tied to performance factors.
The filing shows 599 common shares were withheld at $58.22 per share to cover taxes upon vesting, which is not an open-market sale. An additional 203 shares were moved in an "other" transaction. Following these changes, he directly holds 20,508 common shares, plus indirect holdings through a spouse and a BMS savings plan.
Bristol Myers Squibb EVP and Chief Commercial Officer Adam Lenkowsky reported routine equity award activity involving market share units and common stock. On May 1, 2026, he exercised 1,373 market share units into common stock and recorded related adjustments tied to performance factors.
The filing shows 599 common shares were withheld at $58.22 per share to cover taxes upon vesting, which is not an open-market sale. An additional 203 shares were moved in an "other" transaction. Following these changes, he directly holds 20,508 common shares, plus indirect holdings through a spouse and a BMS savings plan.
Bristol-Myers Squibb reported first-quarter 2026 total revenues of $11,489 million, up 3% from 2025, as strong demand in its Growth Portfolio and for Eliquis offset generic erosion in legacy cancer drugs and pricing pressure, especially in the U.S.
GAAP diluted EPS rose to $1.31 from $1.20, helped by lower amortization of acquired intangibles, while non-GAAP EPS fell to $1.58 from $1.80 mainly because diabetes royalty income ended in 2025. Operating cash flow was $1,104 million, and the company continues a restructuring plan targeting about $2.5 billion in charges and $2.0 billion in annual cost savings by 2027.
Bristol-Myers Squibb reported first-quarter 2026 total revenues of $11,489 million, up 3% from 2025, as strong demand in its Growth Portfolio and for Eliquis offset generic erosion in legacy cancer drugs and pricing pressure, especially in the U.S.
GAAP diluted EPS rose to $1.31 from $1.20, helped by lower amortization of acquired intangibles, while non-GAAP EPS fell to $1.58 from $1.80 mainly because diabetes royalty income ended in 2025. Operating cash flow was $1,104 million, and the company continues a restructuring plan targeting about $2.5 billion in charges and $2.0 billion in annual cost savings by 2027.
Bristol Myers Squibb reported first quarter 2026 revenue of $11.5 billion, up 3% year over year (1% Ex-FX). The Growth Portfolio generated $6.2 billion, rising 12% (9% Ex-FX), while the Legacy Portfolio declined to $5.3 billion, down 6%.
Key products included Eliquis with $4.1 billion in worldwide sales, up 16%, and strong growth from newer brands such as Camzyos, Breyanzi, Reblozyl and Opdualag. U.S. revenue was $7.8 billion, down 1%, and international revenue was $3.7 billion, up 11% (4% Ex-FX).
GAAP diluted EPS increased to $1.31 from $1.20, while non-GAAP EPS decreased to $1.58 from $1.80, reflecting higher research and development spending and lower other income. Net income attributable to the company was $2.7 billion on a GAAP basis and $3.2 billion on a non-GAAP basis.
The company reaffirmed its 2026 non-GAAP guidance, including total revenue of ~$46.0–$47.5 billion and non-GAAP diluted EPS of $6.05–$6.35, with both revenue and EPS expected to trend toward the upper end of these ranges.
Bristol Myers Squibb reported first quarter 2026 revenue of $11.5 billion, up 3% year over year (1% Ex-FX). The Growth Portfolio generated $6.2 billion, rising 12% (9% Ex-FX), while the Legacy Portfolio declined to $5.3 billion, down 6%.
Key products included Eliquis with $4.1 billion in worldwide sales, up 16%, and strong growth from newer brands such as Camzyos, Breyanzi, Reblozyl and Opdualag. U.S. revenue was $7.8 billion, down 1%, and international revenue was $3.7 billion, up 11% (4% Ex-FX).
GAAP diluted EPS increased to $1.31 from $1.20, while non-GAAP EPS decreased to $1.58 from $1.80, reflecting higher research and development spending and lower other income. Net income attributable to the company was $2.7 billion on a GAAP basis and $3.2 billion on a non-GAAP basis.
The company reaffirmed its 2026 non-GAAP guidance, including total revenue of ~$46.0–$47.5 billion and non-GAAP diluted EPS of $6.05–$6.35, with both revenue and EPS expected to trend toward the upper end of these ranges.
Bristol-Myers Squibb Co reported that Vanguard Capital Management beneficially owned 153,108,018 shares of common stock, representing 7.49% of the class as of 03/31/2026. The filing lists sole dispositive power for 153,108,018 shares and sole voting power for 20,787,778 shares. The Schedule 13G was signed on 04/29/2026 by Ashley Grim.
Bristol-Myers Squibb Co reported that Vanguard Capital Management beneficially owned 153,108,018 shares of common stock, representing 7.49% of the class as of 03/31/2026. The filing lists sole dispositive power for 153,108,018 shares and sole voting power for 20,787,778 shares. The Schedule 13G was signed on 04/29/2026 by Ashley Grim.
Bristol Myers Squibb EVP and CFO David V. Elkins reported open-market sales of company stock. On April 1, 2026, he sold 25,519 shares of common stock at a weighted average price of $61.60 per share and 4,481 shares at $62.05 per share, totaling 30,000 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sales, he directly held 159,248 shares of Bristol Myers Squibb common stock and had an additional 294.42 shares held indirectly through the BMS Savings and Investment Program, based on a recent 401(k) plan statement.
Bristol Myers Squibb EVP and CFO David V. Elkins reported open-market sales of company stock. On April 1, 2026, he sold 25,519 shares of common stock at a weighted average price of $61.60 per share and 4,481 shares at $62.05 per share, totaling 30,000 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sales, he directly held 159,248 shares of Bristol Myers Squibb common stock and had an additional 294.42 shares held indirectly through the BMS Savings and Investment Program, based on a recent 401(k) plan statement.
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award. The grant was valued at $60.65 per unit and is linked to an equal number of underlying common shares. Following this award, she holds 43,903.777 Deferred Share Units in total.
The units will convert into common stock when she leaves the board or on a future date she previously chose. Her balance includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award. The grant was valued at $60.65 per unit and is linked to an equal number of underlying common shares. Following this award, she holds 43,903.777 Deferred Share Units in total.
The units will convert into common stock when she leaves the board or on a future date she previously chose. Her balance includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II received a grant of 845.012 Deferred Share Units as compensation. These units are tied to Bristol Myers Squibb common stock at a reference price of $60.65 per unit.
Each Deferred Share Unit converts into one share of common stock when his board service ends or on a future date he previously selected. Following this award, he holds a total of 68,727.516 Deferred Share Units, which also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II received a grant of 845.012 Deferred Share Units as compensation. These units are tied to Bristol Myers Squibb common stock at a reference price of $60.65 per unit.
Each Deferred Share Unit converts into one share of common stock when his board service ends or on a future date he previously selected. Following this award, he holds a total of 68,727.516 Deferred Share Units, which also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.